Compare PROP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | ADAG |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 84.8M |
| IPO Year | N/A | 2021 |
| Metric | PROP | ADAG |
|---|---|---|
| Price | $1.81 | $1.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $6.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 98.5K |
| Earning Date | 11-14-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,577,000.00 | $103,204.00 |
| Revenue This Year | $3,967.26 | $6,983.06 |
| Revenue Next Year | $71.16 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.64 | $1.30 |
| 52 Week High | $10.58 | $3.16 |
| Indicator | PROP | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 54.52 |
| Support Level | $1.67 | $1.92 |
| Resistance Level | $1.92 | $2.06 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 50.91 | 62.50 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.